Aclaris Therapeutics ACRS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2M+37.2% | $1.3M-85.9% | $3.3M-24.1% | $1.78M-35.8% | $1.46M-39.3% | ||
| $395K-21.9% | $532K-24.5% | $538K-17.7% | $515K-17.5% | $506K-37.5% | ||
| $15.66M+35.2% | $16.58M+83.7% | $13.03M+119% | $11.45M+30.7% | $11.58M+17.7% | ||
| $6.74M+9.8% | $5.58M+12.6% | $4.87M-13.8% | $5.39M+13.3% | $6.14M-10.3% | ||
| $102K-20.3% | $102K-28.7% | $110K-38.5% | $114K-52.9% | $128K-47.3% | ||
| $24.19M+23.8% | $24.03M-77.9% | $20.45M+38.0% | $20.19M+29.2% | $19.54M-8.4% | ||
| -$22.19M-22.7% | -$22.73M+77.2% | -$17.15M-63.8% | -$18.41M-43.2% | -$18.08M+4.5% | ||
| -1,111.8%+131pp | -1,755.5%-673pp | -519.8%-279pp | -1,035.9%-571pp | -1,242.9%-453pp | ||
| $1.51M-30.1% | $1.63M-22.3% | $1.82M-8.6% | $2.02M+8.0% | $2.17M+8.8% | ||
| $2.37M-21.0% | $2.94M-5.9% | $2.54M-12.1% | $2.98M+59.5% | $3M+50.7% | ||
| -$19.82M-31.4% | -$19.8M+79.5% | -$14.61M-92.6% | -$15.43M-40.4% | -$15.09M+11.0% | ||
| -993.2%+43.6pp | -1,528.6%-480pp | -443%-268pp | -868.3%-471pp | -1,036.8%-330pp | ||
| -$0.15-25.0% | -$0.16+86.8% | -$0.12-9.1% | -$0.13+13.3% | -$0.12+50.0% | ||
| -$0.15-25.0% | -$0.16+86.8% | -$0.12-9.1% | -$0.13+13.3% | -$0.12+50.0% | ||
| 128.8M+5.2% | 122.6M+58.6% | 122.6M+71.8% | 122.6M+71.9% | 122.4M+72.2% | ||
| 128.8M+5.2% | 122.6M+58.6% | 122.6M+71.8% | 122.6M+71.9% | 122.4M+72.2% | ||
| —— | $400K— | $100K-87.5% | $1.5M+650% | $300K-89.3% | ||
| -$20.41M-38.4% | -$19.78M+79.6% | -$14.5M-117% | -$15.38M-38.8% | -$14.75M+14.3% | ||
| —— | —— | —— | —— | —— | ||
| $1.39M+37.9% | $937K-89.1% | $1.91M+9.0% | $1.34M+3.9% | $1.01M-2.0% | ||
| -$588K-274% | $13K— | $115K-87.1% | $48K+148% | $337K+231% | ||
| -$588K-274% | $13K— | $115K-87.1% | $48K+148% | $337K+231% | ||
| $2M+37.2% | $1.3M-85.9% | $3.3M-24.1% | $1.78M-35.8% | $1.46M-39.3% | ||
| $854K+2.5% | $1.31M+27.9% | $716K-19.9% | $961K— | $833K— | ||
| -$22.19M-22.7% | -$22.73M+77.2% | -$17.15M-63.8% | -$18.41M-43.2% | -$18.08M+4.5% | ||
| -$22.09M-23.0% | -$22.63M+77.3% | -$17.04M-65.6% | -$18.29M-45.1% | -$17.96M+3.9% | ||
| -$22.09M-23.0% | -$22.63M+77.3% | -$17.04M-65.6% | -$18.29M-45.1% | -$17.96M+3.9% | ||
| -1,106.7%+127pp | -1,747.6%-667pp | -516.5%-280pp | -1,029.5%-574pp | -1,234.1%-455pp | ||
| -$22.19M-22.7% | -$22.73M+77.2% | -$17.15M-63.8% | -$18.41M-43.2% | -$18.08M+4.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Aclaris Therapeutics's revenue?
- Aclaris Therapeutics (ACRS) generated $8.4M in revenue over the trailing twelve months, down 52.9% year over year.
- Is Aclaris Therapeutics profitable?
- Aclaris Therapeutics is not currently profitable: it reported a net loss of $69.7M over the trailing twelve months, a -832.6% net margin.
- What are Aclaris Therapeutics's profit margins?
- Gross margin is 76.3% and operating margin is -961.9%, with a -832.6% net margin.
- What is Aclaris Therapeutics's earnings per share?
- Aclaris Therapeutics's diluted EPS over the trailing twelve months is $-0.56.
- Where does Aclaris Therapeutics's income statement data come from?
- Every line is extracted from Aclaris Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
